keyword
MENU ▼
Read by QxMD icon Read
search

Muscle loss and cirrhosis

keyword
https://www.readbyqxmd.com/read/28821966/application-of-transcutaneous-ultrasonography-for-the-diagnosis-of-muscle-mass-loss-in-patients-with-liver-cirrhosis
#1
Kazufumi Kobayashi, Hitoshi Maruyama, Soichiro Kiyono, Sadahisa Ogasawara, Eiichiro Suzuki, Yoshihiko Ooka, Tetsuhiro Chiba, Naoya Kato, Tadashi Yamaguchi
BACKGROUND: To propose an ultrasound-based parameter for the diagnosis of muscle mass loss (MML) in cirrhosis. METHODS: This is an IRB-approved cross-sectional study (October 2013 to January 2017) with written informed consent including 357 subjects-234 cirrhosis and 123 controls. MML was diagnosed using the skeletal muscle index at the L3 level (L3-SMI) on computed tomography (CT). Transcutaneous ultrasound was used to demonstrate a cross section of the right iliopsoas muscle, and the iliopsoas muscle index (IP index) was defined by the iliopsoas muscle area/height(2) (mm(2)/m(2))...
August 18, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28781818/significance-of-psoas-muscle-thickness-as-an-indicator-of-muscle-atrophy-in-patients-with-hepatocellular-carcinoma-treated-with-sorafenib
#2
Mio Yamashima, Hisamitsu Miyaaki, Takuya Honda, Hidetaka Shibata, Satoshi Miuma, Naota Taura, Kazuhiko Nakao
Sarcopenia has been reported to be associated with the prognosis of patients with liver cirrhosis and hepatocellular carcinoma (HCC). The aim of the present study was to determine whether sarcopenia was associated with the prognosis of patients with HCC treated with sorafenib. A total of 40 patients with HCC who were treated with sorafenib were evaluated. As an indicator of skeletal muscle mass, transverse psoas muscle thickness (TPMT) was measured on computed tomography images at the level of the umbilicus prior to treatment initiation and after 1-3 months of treatment...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28777879/sarcopenia-in-hiding-the-risk-and-consequence-of-underestimating-muscle-dysfunction-in-nash
#3
Rahima A Bhanji, Praveena Narayanan, Alina M Allen, Harmeet Malhi, Kymberly D Watt
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Up to one third of individuals with NAFLD will develop non-alcoholic steatohepatitis (NASH), which is associated with progression to cirrhosis and is rapidly becoming the leading indication for liver transplantation. Sarcopenia is defined as a progressive and generalized loss of skeletal muscle mass, strength and function. It is seen in up to 60% of patients with end-stage liver disease and portends a poor prognosis...
August 4, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28665532/characterization-of-body-composition-and-definition-of-sarcopenia-in-patients-with-alcoholic-liver-cirrhosis-a-computed-tomography-based-study
#4
Jaya Benjamin, Varsha Shasthry, Chetan Ramesh Kalal, Lovkesh Anand, Ankit Bhardwaj, Vanshja Pandit, Ankur Arora, Sasidharan Rajesh, Viniyendra Pamecha, Vikas Jain, Guresh Kumar, Anthony Lauria, Puneet Puri, Yogendra Kumar Joshi, Shiv Kumar Sarin
Alterations in body composition (BC) as loss of fat and muscle mass (sarcopenia) are associated with poor outcome in alcoholic liver cirrhosis (ALC). Prevalence of sarcopenia depends upon the method of assessment. Computed Tomography (CT) is a gold standard tool for assessing BC AIM: To characterize BC and define sarcopenia in ALC patients using CT METHODS: Single slice CT images at L3 vertebrae of healthy controls (HC) - organ transplant donors and ALC patients were analysed to give cross-sectional area of five skeletal muscles normalized for height -skeletal muscle index (SMI; cm(2) /m(2) ), area of subcutaneous (SAT;cm(2) ) and visceral adipose tissue (VAT;cm(2) )...
June 30, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28627027/elevated-serum-myostatin-level-is-associated-with-worse-survival-in-patients-with-liver-cirrhosis
#5
Hiroki Nishikawa, Hirayuki Enomoto, Akio Ishii, Yoshinori Iwata, Yuho Miyamoto, Noriko Ishii, Yukihisa Yuri, Kunihiro Hasegawa, Chikage Nakano, Takashi Nishimura, Kazunori Yoh, Nobuhiro Aizawa, Yoshiyuki Sakai, Naoto Ikeda, Tomoyuki Takashima, Ryo Takata, Hiroko Iijima, Shuhei Nishiguchi
BACKGROUND: We aimed to elucidate the relationship between serum myostatin levels and other markers including skeletal muscle mass and to investigate the influence of serum myostatin levels on survival for patients with liver cirrhosis (LC). METHODS: A total of 198 LC subjects were analysed in this study. Myostatin levels were measured using stored sera. We retrospectively investigated the relationship between myostatin level and other markers, and the influence of myostatin level on overall survival (OS)...
June 18, 2017: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/28557005/sarcopenia-in-alcoholic-liver-disease-clinical-and-molecular-advances
#6
REVIEW
Jaividhya Dasarathy, Arthur J McCullough, Srinivasan Dasarathy
Despite advances in treatment of alcohol use disorders that focus on increasing abstinence and reducing recidivism, alcoholic liver disease (ALD) is projected to be the major cause of cirrhosis and its complications. Malnutrition is recognized as the most frequent complication in ALD, and despite the high clinical significance, there are no effective therapies to reverse malnutrition in ALD. Malnutrition is a relatively imprecise term, and sarcopenia or skeletal muscle loss, the major component of malnutrition, is primarily responsible for the adverse clinical consequences in patients with liver disease...
August 2017: Alcoholism, Clinical and Experimental Research
https://www.readbyqxmd.com/read/28462693/sarcopenia-in-patients-with-advanced-liver-disease
#7
Francesca Romana Ponziani, Antonio Gasbarrini
Sarcopenia is the loss of muscle mass and function, affecting up to 70% of patients with advanced liver disease. Liver cirrhosis is characterized by an altered glucose metabolism, lipid oxidation, ketogenesis and protein catabolism, leading to the loss of adipose and muscle tissue. The gastrointestinal dysfunction of cirrhotic patients results in inadequate nutrients intake and is responsible for muscle weakness thus limiting physical exercise and perpetuating the reduction of muscle mass. Recently, alterations of hormonal pathways involved in muscle growth, increased intestinal permeability and changes in the gut microbiota composition have been reported in cirrhotic patients...
April 28, 2017: Current Protein & Peptide Science
https://www.readbyqxmd.com/read/28439569/the-obesity-paradox-in-kidney-disease-how-to-reconcile-it-with-obesity-management
#8
Kamyar Kalantar-Zadeh, Connie M Rhee, Jason Chou, S Foad Ahmadi, Jongha Park, Joline Lt Chen, Alpesh N Amin
Obesity, a risk factor for de novo chronic kidney disease (CKD), confers survival advantages in advanced CKD. This so-called obesity paradox is the archetype of the reverse epidemiology of cardiovascular risks, in addition to the lipid, blood pressure, adiponectin, homocysteine, and uric acid paradoxes. These paradoxical phenomena are in sharp contradistinction to the known epidemiology of cardiovascular risks in the general population. In addition to advanced CKD, the obesity paradox has also been observed in heart failure, chronic obstructive lung disease, liver cirrhosis, and metastatic cancer, as well as in the elderly...
March 2017: KI Reports
https://www.readbyqxmd.com/read/28400317/the-long-winding-road-to-transplant-how-sarcopenia-and-debility-impact-morbidity-and-mortality-on-the-waitlist
#9
Rahima A Bhanji, Elizabeth J Carey, Liu Yang, Kymberly D Watt
Frailty and sarcopenia are common complications of cirrhosis. Frailty has been described as an increased susceptibility to stressors secondary to a cumulative decline in physiologic reserve; this decline occurs with aging or is a result of the disease process, across multiple organ systems. Sarcopenia, a key component of frailty, is defined as progressive and generalized loss of skeletal muscle mass and strength. The presence of either of these complications is associated with increased morbidity and mortality, as these are tightly linked to decompensation and increased complication rates...
April 8, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28208022/protein-requirements-for-critically-ill-patients-with-renal-and-liver-failure
#10
Jayshil J Patel, Craig J McClain, Menaka Sarav, Jill Hamilton-Reeves, Ryan T Hurt
Diseases leading to critical illness induce proteolysis resulting in muscle wasting and negative nitrogen balance. Muscle wasting has been associated with poor intensive care unit (ICU)-related outcomes, including an increased risk for mortality. Acute kidney injury (AKI) represents a common organ dysfunction associated with ICU-related disorders, such as sepsis, trauma, and respiratory failure. AKI and renal replacement therapy lead to amino acid loss. Decompensated liver cirrhosis (DLC) and acute liver failure (ALF) represent more severe forms of liver dysfunction leading to ICU admission...
April 2017: Nutrition in Clinical Practice
https://www.readbyqxmd.com/read/27981407/the-bile-duct-ligated-rat-a-relevant-model-to-study-muscle-mass-loss-in-cirrhosis
#11
Cristina R Bosoi, Mariana M Oliveira, Rafael Ochoa-Sanchez, Mélanie Tremblay, Gabriella A Ten Have, Nicolaas E Deutz, Christopher F Rose, Chantal Bemeur
Muscle mass loss and hepatic encephalopathy (complex neuropsychiatric disorder) are serious complications of chronic liver disease (cirrhosis) which impact negatively on clinical outcome and quality of life and increase mortality. Liver disease leads to hyperammonemia and ammonia toxicity is believed to play a major role in the pathogenesis of hepatic encephalopathy. However, the effects of ammonia are not brain-specific and therefore may also affect other organs and tissues including muscle. The precise pathophysiological mechanisms underlying muscle wasting in chronic liver disease remains to be elucidated...
April 2017: Metabolic Brain Disease
https://www.readbyqxmd.com/read/27775690/knockout-of-microrna-21-reduces-biliary-hyperplasia-and-liver-fibrosis-in-cholestatic-bile-duct-ligated-mice
#12
Lindsey L Kennedy, Fanyin Meng, Julie K Venter, Tianhao Zhou, Walker A Karstens, Laura A Hargrove, Nan Wu, Konstantina Kyritsi, John Greene, Pietro Invernizzi, Francesca Bernuzzi, Shannon S Glaser, Heather L Francis, Gianfranco Alpini
Cholestasis is a condition that leads to chronic hepatobiliary inflammation, fibrosis, and eventually cirrhosis. Many microRNAs (miRs) are known to have a role in fibrosis progression; however, the role of miR-21 during cholestasis remains unknown. Therefore, the aim of this study was to elucidate the role of miR-21 during cholestasis-induced biliary hyperplasia and hepatic fibrosis. Wild-type (WT) and miR-21(-/-) mice underwent Sham or bile duct ligation (BDL) for 1 week, before evaluating liver histology, biliary proliferation, hepatic stellate cell (HSC) activation, fibrotic response, and small mothers against decapentaplegic 7 (Smad-7) expression...
December 2016: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://www.readbyqxmd.com/read/27672278/clinical-characteristics-of-drug-induced-liver-injury-and-primary-biliary-cirrhosis
#13
Jun Yang, Ya-Li Yu, Yu Jin, Ying Zhang, Chang-Qing Zheng
AIM: To summarize and compare the clinical characteristics of drug-induced liver injury (DILI) and primary biliary cirrhosis (PBC). METHODS: A total of 124 patients with DILI and 116 patients with PBC treated at Shengjing Hospital Affiliated to China Medical University from 2005 to 2013 were included. Demographic data (sex and age), biochemical indexes (total protein, albumin, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, indirect bilirubin, alkaline phosphatase, and gamma glutamyltransferase), immunological indexes [immunoglobulin (Ig) A, IgG, IgM, antinuclear antibody, anti-smooth muscle antibody, anti-mitochondrial antibody, and anti-mitochondrial antibodies] and pathological findings were compared in PBC patients, untyped DILI patients and patients with different types of DILI (hepatocellular type, cholestatic type and mixed type)...
September 7, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27577096/functional-human-and-murine-tissue-engineered-liver-is-generated-from-adult-stem-progenitor-cells
#14
Nirmala Mavila, Andrew Trecartin, Ryan Spurrier, Yi Xiao, Xiaogang Hou, David James, Xiaowei Fu, Brian Truong, Clara Wang, Gerald S Lipshutz, Kasper S Wang, Tracy C Grikscheit
: Liver disease affects large numbers of patients, yet there are limited treatments available to replace absent or ineffective cellular function of this crucial organ. Donor scarcity and the necessity for immunosuppression limit one effective therapy, orthotopic liver transplantation. But in some conditions such as inborn errors of metabolism or transient states of liver insufficiency, patients may be salvaged by providing partial quantities of functional liver tissue. After transplanting multicellular liver organoid units composed of a heterogeneous cellular population that includes adult stem and progenitor cells, both mouse and human tissue-engineered liver (TELi) form in vivo...
August 30, 2016: Stem Cells Translational Medicine
https://www.readbyqxmd.com/read/27573411/ammonia-elicits-a-different-myogenic-response-in-avian-and-murine-myotubes
#15
Rachel A Stern, Srinivasan Dasarathy, Paul E Mozdziak
Increased myostatin expression, resulting in muscle loss, has been associated with hyperammonemia in mammalian models of cirrhosis. However, there is evidence that hyperammonemia in avian embryos results in a reduction of myostatin expression, suggesting a proliferative myogenic environment. The present in vitro study examines species differences in myotube and liver cell response to ammonia using avian and murine-derived cells. Primary myoblasts and liver cells were isolated from embryonic day 15 and 17 chick embryos to be compared with mouse myoblasts (C2C12) and liver (AML12) cells...
February 2017: In Vitro Cellular & Developmental Biology. Animal
https://www.readbyqxmd.com/read/27515775/sarcopenia-from-mechanism-to-diagnosis-and-treatment-in-liver-disease
#16
REVIEW
Srinivasan Dasarathy, Manuela Merli
Sarcopenia or loss of skeletal muscle mass is the major component of malnutrition and is a frequent complication in cirrhosis that adversely affects clinical outcomes. These include survival, quality of life, development of other complications and post liver transplantation survival. Radiological image analysis is currently utilized to diagnose sarcopenia in cirrhosis. Nutrient supplementation and physical activity are used to counter sarcopenia but have not been consistently effective because the underlying molecular and metabolic abnormalities persist or are not influenced by these treatments...
December 2016: Journal of Hepatology
https://www.readbyqxmd.com/read/27493866/sarcopenic-obesity-and-myosteatosis-are-associated-with-higher-mortality-in-patients-with-cirrhosis
#17
Aldo J Montano-Loza, Paul Angulo, Judith Meza-Junco, Carla M M Prado, Michael B Sawyer, Crystal Beaumont, Nina Esfandiari, Mang Ma, Vickie E Baracos
BACKGROUND AND AIMS: Obesity is frequently associated with cirrhosis, and cirrhotic patients may develop simultaneous loss of skeletal muscle and gain of adipose tissue, culminating in the condition of sarcopenic obesity. Additionally, muscle depletion is characterized by both a reduction in muscle size and increased proportion of muscular fat, termed myosteatosis. In this study, we aimed to establish the frequency and clinical significance of sarcopenia, sarcopenic obesity and myosteatosis in cirrhotic patients...
May 2016: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/27399349/impaired-follistatin-secretion-in-cirrhosis
#18
COMPARATIVE STUDY
Anders Rasmussen Rinnov, Peter Plomgaard, Bente Klarlund Pedersen, Lise Lotte Gluud
CONTEXT: Follistatin is a liver-derived inhibitor of the muscle-growth inhibitor myostatin. Reduction in acute follistatin release may help explain muscle loss in liver cirrhosis. OBJECTIVE: The study aimed to investigate the capacity of acute follistatin release in patients with liver cirrhosis compared to healthy control participants. DESIGN, SETTING, AND PARTICIPANTS: To experimentally increase the glucagon-insulin ratio (mimicking the hormonal effect of exercise), we infused glucagon/somatostatin (to inhibit insulin secretion) and compared the acute follistatin increase in eight male cirrhosis patients with eight healthy control participants...
September 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27384305/male-11%C3%AE-hsd1-knockout-mice-fed-trans-fats-and-fructose-are-not-protected-from-metabolic-syndrome-or-nonalcoholic-fatty-liver-disease
#19
Dean P Larner, Stuart A Morgan, Laura L Gathercole, Craig L Doig, Phil Guest, Christopher Weston, Jon Hazeldine, Jeremy W Tomlinson, Paul M Stewart, Gareth G Lavery
Nonalcoholic fatty liver disease (NAFLD) defines a spectrum of conditions from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis and is regarded as the hepatic manifestation of the metabolic syndrome. Glucocorticoids can promote steatosis by stimulating lipolysis within adipose tissue, free fatty acid delivery to liver and hepatic de novo lipogenesis. Glucocorticoids can be reactivated in liver through 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme activity. Inhibition of 11β-HSD1 has been suggested as a potential treatment for NAFLD...
September 2016: Endocrinology
https://www.readbyqxmd.com/read/27318325/metabolic-adaptation-of-skeletal-muscle-to-hyperammonemia-drives-the-beneficial-effects-of-l-leucine-in-cirrhosis
#20
Gangarao Davuluri, Dawid Krokowski, Bo-Jhih Guan, Avinash Kumar, Samjhana Thapaliya, Dharmvir Singh, Maria Hatzoglou, Srinivasan Dasarathy
BACKGROUND & AIMS: Increased skeletal muscle ammonia uptake with loss of muscle mass adversely affects clinical outcomes in cirrhosis. Hyperammonemia causes reduced protein synthesis and sarcopenia but the cellular responses to impaired proteostasis and molecular mechanism of l-leucine induced adaptation to ammonia induced stress were determined. METHODS: Response to activation of amino acid deficiency sensor, GCN2, in the skeletal muscle from cirrhotic patients and the portacaval anastomosis (PCA) rat were quantified...
November 2016: Journal of Hepatology
keyword
keyword
86700
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"